Sanofi Pasteur And South Korea’s SK Chemical To Jointly Develop PCV
This article was originally published in PharmAsia News
Executive Summary
Sanofi’s vaccine arm hopes to develop its first pneumococcal conjugate jab with the help of South Korea’s SK Chemical, tapping into the growing need to fight new bacteria strains and combat antibiotic resistance in South Asia and elsewhere.